UCL Cancer Institute


Cellular therapies to prevent or treat post-transplant relapse

Research theme 3

Theme Lead: Dr Claire Roddie (formerly: Professor Karl Peggs)

T-cell therapies

The researchers in this theme have in-depth knowledge and experience of the use of unmanipulated donor lymphocyte infusions (DLIs) both to prevent and treat relapse following stem cell transplants. Whilst the anti-tumour activity of DLIs is well established, graft-versus-host disease (GvHD) is the major toxicity, which may be fatal. Separation of GvHD from graft-versus-tumour activity is difficult as they largely depend on the same T-cell receptor (TCR)-mediated recognition of different tissue-specific antigens. 

Our goal is to advance developments in genetically modified T-cell therapies to improve outcomes in post-transplant relapse.

  • Find out more about UCL CAR T programme 
  • Read the publication of result from the ALLCAR19 study in the Journal of Clinical Oncology on 31 August 2021:

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Roddie C, Dias J, O'Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, Hartley JA, Spanswick V, Lowe H, Popova B, Clifton-Hadley L, Wheeler G, Olejnik J, Bloor A, Irvine D, Wood L, Marzolini MAV, Domning S, Farzaneh F, Lowdell MW, Linch DC, Pule MA, Peggs KS. J Clin Oncol. 2021 Oct 20;39(30):3352-3363. doi: 10.1200/JCO.21.00917. Epub 2021 Aug 31. PMID: 34464155